Abstract: The invention relates to a method for preparative production of long nucleic acids by PCR. The method involves the following hybridization steps: a) a nucleic acid base sequence is hybridized on the 3? and 5? ends with an adapter primer; b) the product from step a) is hybridized on the 3? and 5? ends with an extension primer containing an extension sequence, wherein a nucleic acid with extension sequences amplified and enlarged in the 3? and 5? ends of the nucleic acid base sequence is then formed from the nucleic acid base sequence. The invention also relates to different applications of the inventive method.

Abstract: The invention relates to a method for preparative production of long nucleic acids by PCR. The method involves the following hybridization steps: a) a nucleic acid base sequence is hybridized on the 3? and 5? ends with an adapter primer; b) the product from step a) is hybridized on the 3? and 5? ends with an extension primer containing an extension sequence, wherein a nucleic acid with extension sequences amplified and enlarged in the 3? and 5? ends of the nucleic acid base sequence is then formed from the nucleic acid base sequence. The invention also relates to different applications of the inventive method.

Abstract: The present invention relates to an active substance release system containing two compounds. The first compound comprises a nanoparticle, combined with an oligonucleotide inhibition strand that is hybridized with a catalytically active nucleic acid. The second compound comprises a carrier, combined with a substrate molecule that is coupled to a therapeutic active substance. By means of external stimulation, the catalytically active nucleic acid of the first compound is released and specifically binds to the substrate molecule of the second compound. This leads to cleavage of the substrate molecule, whereby the active substance bound thereto is released.

Abstract: The invention relates to a method for preparative production of long nucleic acids by PCR. The method involves the following hybridization steps: a) a nucleic acid base sequence is hybridized on the 3? and 5? ends with an adapter primer; b) the product from step a) is hybridized on the 3? and 5? ends with an extension primer containing an extension sequence, wherein a nucleic acid with extension sequences amplified and enlarged in the 3? and 5? ends of the nucleic acid base sequence is then formed from the nucleic acid base sequence. The invention also relates to different applications of the inventive method.

Abstract: The invention relates to the use of an L-ribozyme, which is capable of splitting an L-RNA in the region of a target sequence of the L-RNA, in order to produce a pharmaceutical composition for trating undesired physiological adverse reactions due to the administration of a therapeautic modecule containing the L-RNA. Alternatively, an endogeneous target RNA may also be split by the L-ribozyme.

Abstract: The invention relates to the use of an L-DNA which is capable of binding to an L-RNA, in particular in an antisense reaction, and optionally of cleaving the L-RNA in the range of a target sequence of the L-RNA, for preparing a pharmaceutical composition for the treatment of undesired physiological side reactions due to the administration of a therapeutic molecule containing the L-RNA. The L-DNA can alternatively also be used for cleaving an endogenous target RNA or DNA.

Abstract: The invention relates to the use of an L-ribozyme, which is capable of splitting an L-RNA in the region of a target sequence of the L-RNA, in order to produce a pharmaceutical composition for trating undesired physiological adverse reactions due to the administration of a therapeautic modecule containing the L-RNA. Alternatively, an endogeneous target RNA may also be split by the L-ribozyme.

Abstract: The present invention relates to an active substance release system containing two compounds. The first compound comprises a nanoparticle, combined with an oligonucleotide inhibition strand that is hybridized with a catalytically active nucleic acid. The second compound comprises a carrier, combined with a substrate molecule that is coupled to a therapeutic active substance. By means of external stimulation, the catalytically active nucleic acid of the first compound is released and specifically binds to the substrate molecule of the second compound. This leads to cleavage of the substrate molecule, whereby the active substance bound thereto is released.

Abstract: The invention relates to the use of an L-ribozyme, which is capable of splitting an L-RNA in the region of a target sequence of the L-RNA, in order to produce a pharmaceutical composition for treating undesired physiological adverse reactions due to the administration of a therapeutic molecule containing the L-RNA. Alternatively, an endogenous target RNA may also be split by the L-ribozyme.

Abstract: The invention relates to novel streptavidin binding peptides.

Abstract: Antisense oligodeoxynucleotides against VR1, corresponding nucleotide constructs, cells containing said nucleotide constructs, pharmaceutical and diagnostic substances, uses thereof in pain therapy, and methods for diagnosing symptoms related to VR1 and for identifying pain-modulating substances.

Abstract: Antisense oligodeoxynucleotides against VR1, corresponding nucleotide constructs, cells containing said nucleotide constructs, pharmaceutical and diagnostic substances, uses thereof in pain therapy, and methods for diagnosing symptoms related to VR1 and for identifying pain-modulating substances.

Abstract: The invention relates to a nucleic acid library or protein or peptide library in the form of a two-dimensionally resolved grid-type arrangement with a plurality of grid elements. Every grid element contains, on the statistical average, a defined number of nucleic acid types or protein or peptide types having a respective specific sequence structure. The inventive library is further characterized in that the grid elements are configured as capillary hollow spaces. The capillary axes of said capillary hollow spaces are in parallel to one another and the openings of different capillary hollow spaces are arranged in a grid area. The invention further relates to various uses of such a library.

Abstract: The invention relates to a method for gene expression in a cell-free transcription/translation system, the reaction solution containing all the components necessary for the transcription/translation mechanism, amino acids, nucleotides, metabolic components which provide energy and which are necessary for synthesis, and the proteins arising during translation being immobilized on a matrix.

Abstract: The present invention relates to DNA enzymes of type 10-23 with certain modifications of specific nucleotides in the core sequence rendering the DNA enzymes particularly stable and additionally exhibiting substantially the same or a higher cleavage efficiency with respect to their substrate when compared against the corresponding unmodified DNA enzymes. The present application further provides host cells containing the DNA enzymes according to the invention. In addition there is provided a pharmaceutical formulation which contains the DNA enzymes or host cells according to the invention. The DNA enzymes and further subjects are directed in particular against the vanilloid receptor 1 (VR1), or picornaviruses. The present invention further provides small interference RNA molecules (siRNA) directed against VR1, and host cells containing the siRNA.

Abstract: The invention relates to novel streptavidin binding peptides.

Abstract: The invention relates to a method for preparative production of long nucleic acids by PCR. The method involves the following hybridization steps: a) a nucleic acid base sequence is hybridized on the 3? and 5? ends with an adapter primer; b) the product from step a) is hybridized on the 3? and 5? ends with an extension primer containing an extension sequence, wherein a nucleic acid with extension sequences amplified and enlarged in the 3? and 5? ends of the nucleic acid base sequence is then formed from the nucleic acid base sequence. The invention also relates to different applications of the inventive method.

Abstract: The invention relates to a method for gene expression in a cell-free transcription/translation system, the reaction solution containing all the components necessary for the transcription/translation mechanism, amino acids, nucleotides, metabolic components which provide energy and which are necessary for synthesis, and the proteins arising during translation being immobilized on a matrix.

Abstract: The invention relates to a nucleic acid library or protein or peptide library in the form of a two-dimensionally resolved grid-type arrangement with a plurality of grid elements. Every grid element contains, on the statistical average, a defined number of nucleic acid types or protein or peptide types having a respective specific sequence structure. The inventive library is further characterized in that the grid elements are configured as capillary hollow spaces. The capillary axes of said capillary hollow spaces are in parallel to one another and the openings of different capillary hollow spaces are arranged in a grid area. The invention further relates to various uses of such a library.

Abstract: Antisense oligodeoxynucleotides against VR1, corresponding nucleotide constructs, cells containing said nucleotide constructs, pharmaceutical and diagnostic substances, uses thereof in pain therapy, and methods for diagnosing symptoms related to VR1 and for identifying pain-modulating substances.